Working to Eradicate Gynecologic Cancers

Joan Leslie Walker, MD

Professor, James A. Merrill Chair, Gynecologic Oncology
The University of Oklahoma
Dept. of OB/GYN
800 NE 10th St
Suite 5050
Oklahoma City, OK
USA 73104


Biographical Sketch:
GOG Co-Chair cancer prevention and control. PI NCI SUCCEED BIOMARKERS IN CERVICAL CANCER. Currently driving toward ovarian cancer risk reduction with OCP And salpingectomy followed by oophorectomy in high risk women. Salpingectomy alone in average risk women.

Papers:
12 - Focused Plenary Operative outcomes among a geriatric population of endometrial cancer patients: an ancillary data analysis of Gynecologic Oncology Group study LAP2 62 - Scientific Plenary Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, Fallopian tube, and peritoneal cancers 76 - Focused Plenary Complications and surgical staging of endometrial cancer with respect to obesity: a Gynecologic Oncology Group LAP2 ancillary data study 96 - Featured Poster Patient and physician factors associated with participation in Gynecologic Oncology Group (GOG) trials in cervical and uterine cancer 118 - Featured Poster Patterns of recurrence and survival after randomization to laparoscopy versus laparotomy in women with high-grade uterine cancer: a Gynecologic Oncology Group (GOG) study 139 - Scientific Plenary Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in combination with carboplatin with or without bevacizumab for primary ovarian cancer: Gynecologic Oncology Group study 262 437 - Poster Session B The impact of obesity on pathologic features and survival with endometrial cancer: a Gynecologic Oncology Group (GOG) LAP2 ancillary data study Discussant